Cantor Fitzgerald Forecasts AGIO FY2026 Earnings

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) - Cantor Fitzgerald issued their FY2026 earnings estimates for shares of Agios Pharmaceuticals in a research note issued on Monday, June 9th. Cantor Fitzgerald analyst E. Schmidt expects that the biopharmaceutical company will post earnings of ($6.13) per share for the year. The consensus estimate for Agios Pharmaceuticals' current full-year earnings is ($6.85) per share.

A number of other equities analysts also recently issued reports on the company. Scotiabank lowered their price target on Agios Pharmaceuticals from $74.00 to $71.00 and set a "sector outperform" rating on the stock in a research report on Friday, May 2nd. HC Wainwright initiated coverage on Agios Pharmaceuticals in a research report on Monday, February 24th. They set a "buy" rating and a $58.00 target price on the stock. Finally, Wall Street Zen cut shares of Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Monday, May 19th. One analyst has rated the stock with a sell rating, three have issued a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Hold" and an average price target of $56.50.

Agios Pharmaceuticals Stock Down 0.6%

Shares of NASDAQ:AGIO traded down $0.20 during trading on Tuesday, reaching $34.30. 478,627 shares of the company's stock traded hands, compared to its average volume of 663,099. Agios Pharmaceuticals has a fifty-two week low of $23.42 and a fifty-two week high of $62.58. The company has a 50-day simple moving average of $29.76 and a 200-day simple moving average of $33.75. The firm has a market cap of $1.99 billion, a PE ratio of 3.02 and a beta of 0.73.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The biopharmaceutical company reported ($1.55) earnings per share for the quarter, beating analysts' consensus estimates of ($1.80) by $0.25. Agios Pharmaceuticals had a net margin of 1,845.92% and a negative return on equity of 2.51%. The company had revenue of $8.73 million during the quarter, compared to analysts' expectations of $9.86 million.

Insider Activity

In related news, Director Jacqualyn A. Fouse sold 7,497 shares of the business's stock in a transaction that occurred on Thursday, April 10th. The stock was sold at an average price of $25.90, for a total transaction of $194,172.30. Following the completion of the sale, the director now directly owns 149,220 shares in the company, valued at approximately $3,864,798. The trade was a 4.78% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 4.93% of the company's stock.

Institutional Investors Weigh In On Agios Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Envestnet Asset Management Inc. lifted its stake in shares of Agios Pharmaceuticals by 3.3% in the fourth quarter. Envestnet Asset Management Inc. now owns 24,805 shares of the biopharmaceutical company's stock worth $815,000 after buying an additional 795 shares in the last quarter. Venturi Wealth Management LLC acquired a new stake in Agios Pharmaceuticals in the 4th quarter valued at about $33,000. Vanguard Group Inc. raised its holdings in Agios Pharmaceuticals by 1.5% in the 4th quarter. Vanguard Group Inc. now owns 5,631,321 shares of the biopharmaceutical company's stock valued at $185,045,000 after acquiring an additional 85,339 shares during the last quarter. Northern Trust Corp lifted its stake in Agios Pharmaceuticals by 0.9% in the 4th quarter. Northern Trust Corp now owns 595,480 shares of the biopharmaceutical company's stock worth $19,567,000 after purchasing an additional 5,372 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its holdings in shares of Agios Pharmaceuticals by 48.8% during the 4th quarter. Bank of New York Mellon Corp now owns 265,514 shares of the biopharmaceutical company's stock worth $8,725,000 after purchasing an additional 87,089 shares during the last quarter.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.